Loading quotes...
Forecast
| Buy |
2 |
| Hold |
0 |
| Sell |
0 |
News Go to news feed
Phio Pharmaceuticals secures patent grants in US, Canada and Japan
Phio Pharmaceuticals reports three patent allowances and one grant decision to protect its INTASYL active agents in the US, Canada and Japan. The portfolio now comprises 54 granted patents covering chemistry, gene targets, immuno-oncology agents and indications. The company views the expanded protection as supporting strategic partnerships and commercialization, but with a market capitalization of USD 11.97 million and a negative free cash flow of USD 10.72 million it remains in the capital-intensive clinical development phase. The stock trades below InvestingPro’s fair-value estimate. » More on de.investing.com
Financials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | -876.21 | 99.90% |
| Net profit | -3.63M | 97.30% |
| EBITDA | -3.74M | 103.50% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €12.04M |
Number of shares | 11.62M |
52-week high/low | €3.62 - €0.70 |
| Dividends | No |
Beta | 0.79 |
P/E ratio | -0.90 |
PEG ratio | -0.01 |
P/B ratio | 1.11 |
P/S ratio | 0.00 |
Company profile
| Name | Phio Pharmaceuticals Corp |
| CEO | Robert L. Bitterman |
| Employees | 6 |
Discover assets
Shareholders of Phio Pharmaceuticals Corp also invest in the following assets
